Literature DB >> 18061141

Expression, regulation and function of trail in atherosclerosis.

Mary M Kavurma1, Martin R Bennett.   

Abstract

Atherosclerosis is a condition where vascular smooth muscle cells (VSMCs), inflammatory cells, lipids, cholesterol and cellular waste accumulate in the inner lining of an artery, producing a fibro-fatty plaque and resulting in the thickening of the arterial wall. The tumor necrosis factor (TNF) family of cytokines plays a major role in the progression of atherosclerosis. Recently, TNF-related apoptosis-inducing ligand (TRAIL), a member of the TNF superfamily, has been implicated in the development of atherosclerosis since it has been detected in normal and diseased atherosclerotic tissue. Not only is TRAIL involved in apoptosis and immune regulation, recent studies have provided a new function of TRAIL on vascular cells, such that TRAIL can promote endothelial cell (EC) and VSMCs migration and proliferation. In addition, TRAIL is implicated in regulating vascular tone. This review discusses our current understanding of TRAIL expression, regulation and function, and summarises the recent data implicating a role for TRAIL in atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18061141     DOI: 10.1016/j.bcp.2007.10.020

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  27 in total

Review 1.  Control of death receptor ligand activity by posttranslational modifications.

Authors:  R Weinlich; T Brunner; G P Amarante-Mendes
Journal:  Cell Mol Life Sci       Date:  2010-03-20       Impact factor: 9.261

2.  TNF-related apoptosis-inducing ligand promotes human preadipocyte proliferation via ERK1/2 activation.

Authors:  Jan-Bernd Funcke; Verena Zoller; Muad Abd El Hay; Klaus-Michael Debatin; Martin Wabitsch; Pamela Fischer-Posovszky
Journal:  FASEB J       Date:  2015-04-09       Impact factor: 5.191

3.  Advanced glycation end products promote human aortic smooth muscle cell calcification in vitro via activating NF-κB and down-regulating IGF1R expression.

Authors:  Yi Wang; Zhen-yu Zhang; Xiao-qing Chen; Xiang Wang; Heng Cao; Shao-wen Liu
Journal:  Acta Pharmacol Sin       Date:  2013-02-18       Impact factor: 6.150

4.  TNF-related apoptosis-inducing ligand (TRAIL) protects against diabetes and atherosclerosis in Apoe ⁻/⁻ mice.

Authors:  B A Di Bartolo; J Chan; M R Bennett; S Cartland; S Bao; B E Tuch; M M Kavurma
Journal:  Diabetologia       Date:  2011-10-01       Impact factor: 10.122

5.  The relationship between circulating TRAIL and endothelial dysfunction in subclinical hypothyroidism.

Authors:  Guangda Xiang; Ling Yue; Junxia Zhang; Lin Xiang; Jing Dong
Journal:  Endocrine       Date:  2014-10-08       Impact factor: 3.633

6.  Genetic variation in APOJ, LPL, and TNFRSF10B affects plasma fatty acid distribution in Alaskan Eskimos.

Authors:  V Saroja Voruganti; Shelley A Cole; Sven O E Ebbesson; Harald H H Göring; Karin Haack; Sandra Laston; Charlotte R Wenger; M Elizabeth Tejero; Richard B Devereux; Richard R Fabsitz; Jean W MacCluer; Jason G Umans; Barbara V Howard; Anthony G Comuzzie
Journal:  Am J Clin Nutr       Date:  2010-04-21       Impact factor: 7.045

Review 7.  Transcriptional regulation of tumour necrosis factor-related apoptosis-inducing ligand.

Authors:  Nor Saadah M Azahri; Mary M Kavurma
Journal:  Cell Mol Life Sci       Date:  2013-01-18       Impact factor: 9.261

Review 8.  T cells in arteritis and atherosclerosis.

Authors:  Cornelia M Weyand; Brian R Younge; Jörg J Goronzy
Journal:  Curr Opin Lipidol       Date:  2008-10       Impact factor: 4.776

Review 9.  Therapeutic applications of TRAIL receptor agonists in cancer and beyond.

Authors:  Gustavo P Amarante-Mendes; Thomas S Griffith
Journal:  Pharmacol Ther       Date:  2015-09-05       Impact factor: 12.310

10.  Lysosome-dependent Ca(2+) release response to Fas activation in coronary arterial myocytes through NAADP: evidence from CD38 gene knockouts.

Authors:  Fan Zhang; Min Xia; Pin-Lan Li
Journal:  Am J Physiol Cell Physiol       Date:  2010-03-03       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.